-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-517457-27-00
5
2025-06-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-517262-41-00
5
2025-02-28
Juvenile Psoriatic Arthritis (JPsA)
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2023-507227-36-00
5
2025-02-21
SARS-CoV-2 (COVID-19) infection
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2023-505204-34-00
1
2024-12-30
Mature B-Cell Neoplasm,
Non-Hodgkin Lymphoma,
Diffuse large B-cell lym
-
2024-510900-34-00
1
2024-11-22
Solid Tumors
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2023-507776-42-00
5
2024-11-14
Non-small cell lung cancer
-
2022-502972-22-00
5
2024-10-31
Clostridioides difficile infection.
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-508760-29-00
5
2024-10-21
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)